INSTADOSE PHARMA CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -.--% |
|
-.--% | -.--% |
Income Statement Evolution (Annual data)
| Fiscal Period: November | 2020 | 2021 |
|---|---|---|
| Net sales | - | - |
| EBITDA | - | - |
| EBIT 1 | -0.0257 | -0.462 |
| Operating Margin | - | - |
| Earnings before Tax (EBT) 1 | -0.0257 | -0.462 |
| Net income 1 | -0.0257 | -0.462 |
| Net margin | - | - |
| EPS 2 | -0.000342 | -0.006160 |
| Free Cash Flow | - | - |
| FCF margin | - | - |
| FCF Conversion (EBITDA) | - | - |
| FCF Conversion (Net income) | - | - |
| Dividend per Share | - | - |
| Announcement Date | 15/03/22 | 15/03/22 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: November | 2020 | 2021 |
|---|---|---|
| Net Debt 1 | - | - |
| Net Cash position 1 | 0 | - |
| Leverage (Debt/EBITDA) | - | - |
| Free Cash Flow | - | - |
| ROE (net income / shareholders' equity) | - | 378% |
| ROA (Net income/ Total Assets) | - | - |
| Assets 1 | - | - |
| Book Value Per Share 2 | -0 | -0 |
| Cash Flow per Share 2 | - | - |
| Capex | - | - |
| Capex / Sales | - | - |
| Announcement Date | 15/03/22 | 15/03/22 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 531 | |
| +11.78% | 2.97B | |
| -46.69% | 1.87B | |
| -1.63% | 1.31B | |
| -3.01% | 1.03B | |
| -1.51% | 762M | |
| +28.03% | 658M | |
| -23.08% | 428M | |
| -11.16% | 329M | |
| -13.66% | 322M |
- Stock Market
- Equities
- INSD Stock
- Financials Instadose Pharma Corp.
